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Hepatic cirrhosis is one of the leading causes of death worldwide, especially if complicated by ascites. This chronic condition can
be related to the classical disease entity jalodara in Traditional Indian Medicine (Ayurveda). The present paper aims to evaluate
the general potential of Ayurvedic therapy for overall clinical outcomes in hepatic cirrhosis complicated by ascites (HCcA). In
form of a nonrandomized, uncontrolled, single group, open-label observational clinical study, 56 patients fulfilling standardized
diagnostic criteria for HCcA were observed during their treatment at the P. D. Patel Ayurveda Hospital, Nadiad, India. Based on
Ayurvedic tradition, a standardized treatment protocol was developed and implemented, consisting of oral administration of single
and compound herbal preparations combined with purificatory measures as well as dietary and lifestyle regimens. The outcomes
were assessed bymeasuring liver functions through specific clinical features and laboratory parameters and by evaluating the Child-
Pugh prognostic grade score. After 6 weeks of treatment and a follow-up period of 18 weeks, the outcomes showed statistically
significant and clinically relevant improvements. Further larger and randomized trials on effectiveness, safety, and quality of the
Ayurvedic approach in the treatment of HCcA are warranted to support these preliminary findings.
1. Introduction
Hepatic cirrhosis, especially if complicated by ascites, causes
remarkable damage in human health and lives. Its manage-
ment involves high costs for health care systems worldwide.
Liver transplantation as one of the few treatment options
bears risks and is largely unavailable or unaffordable for
common patients in many countries, particularly in India.
Therefore, alternative treatment measures are desirable.
Due to the high prevalence of chronic hepatic diseases
in South Asia, Traditional Indian Medicine (Ayurveda) has
generated extensive empirical knowledge in their treatment
over several centuries.
In addition to observations of successfully treated cases
in Ayurvedic clinics, preliminary scientific findings suggest
that an exploration of traditional Ayurvedic literature and
commonly implemented Ayurvedic treatment modalities
might be worthwhile in this field.
Hepatic Cirrhosis—Epidemiological Data Worldwide. Hepatic
cirrhosis represents the end stage of most chronic liver
diseases, which can remain compensated for many years
[1]. Decompensated cirrhosis can be characterized by the
development of major complications like jaundice, variceal
hemorrhage, ascites, or encephalopathy [2], of which ascites
is the most common [3]. Approximately 50% of patients with
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compensated cirrhosis develop ascites over a period of 10
years [4].The occurrence of ascites is often a landmark in the
natural progress of cirrhosis, as it requires hospitalization and
many patients are referred for liver transplantation [3, 5–7].
In this sense, the disease carries the risk of life-threatening
complications, partly due to a number of comorbidities.
Established cirrhosis has a 10-year mortality of 34–66%,
being largely dependent on the cause of cirrhosis; alcoholic
cirrhosis has a worse prognosis than primary biliary cirrhosis
and cirrhosis due to viral hepatitis [8]. Approximately 15%
of patients with ascites die within the first 12 months after
diagnosis and 44% within the first 60 months [9].
A recent survey reviewed 260 epidemiological studies on
liver diseases in Europe. Alcohol consumption, viral hepatitis
B and C, and metabolic syndromes related to obesity are the
leading causes of cirrhosis and primary liver cancer here.
Liver cirrhosis is responsible for around 170,000 deaths in
Europe annually [10]. In the UK, liver disease is the 5th most
common cause of death [11]. In the United States, chronic
liver disease and cirrhosis ranked 12th among the leading
causes of death in 2010 [12]. Figures are likely to be even
higher in Asia and Africa, since childhood infection with
HCV is more common there and the prevalence of cirrhosis
in patients with chronic HCV increases with increasing
duration of infection [13, 14].
In the course of the rising frequency of alcoholic and
nonalcoholic fatty liver disease, a huge increase in the burden
of liver diseases is expected over the next years [4]. In the
UK, admissions to hospital and liver deaths are both rising
at between 8 and 10% per year. Patients are presenting and
dying from liver disease at an earlier age; the average age
of death from liver disease is 59 years. Over the last 10
years there has been a 5-fold increase in the development
of cirrhosis in 35- to 55-year-old patients [11]. Because
of the increasing prevalence of chronic viral hepatitis and
steatohepatitis and their high risk evolution toward end stage
liver cirrhosis, preventive programs and early management
of these conditions are considered as emerging health issues
worldwide [14]. Treatments that may halt the progression of
compensated to decompensated cirrhosis are currently being
developed [15]. Liver transplantation, however, is the only
option in patients with end stage disease. The cost of hepatic
cirrhosis in terms of human suffering, hospital costs, and lost
productivity is high [16, 17].
Hepatic Cirrhosis in India. Given the high incidence and
prevalence of hepatitis B, hepatitis C, and fatty liver disease,
hepatic cirrhosis is a common condition in India. Generally,
Indian patients first seek help from conventional medicine,
and in many cases liver transplantation is suggested to them.
Actually, India would require up to 20,000 liver transplants
per year. However, currently just 200–300 transplants per
annum are possible within the framework of the Indianmed-
ical system. Liver transplantations are complex procedures;
they require sophisticated infrastructures, expert medical
teams, preservation of the transplant organs, expensive drugs,
and prolonged stays in ICUs, all of which add significantly
to the overall costs. A liver transplant requires about 50,000
USD, plus a lifelong commitment to immunosuppressants,
costing about 2,500 USD per month, which is unmanageable
for most Indian patients [18].
As to our observation, since the only curative yet unaf-
fordable treatment option is liver transplantation in con-
ventional medicine, in India, complementary and alternative
medicine (CAM) treatments are often sought out instead,
especially Ayurveda, the most established traditional whole
medical system (WMS) in South Asia with a well developed
infrastructure, recognized by theWorldHealthOrganization.
(In the context of this paper, though useful for a reader
not familiar with WMS Ayurveda, a detailed description of
Ayurvedic medicine does not seem appropriate here. The
interested reader may gather detailed information on the
current infrastructure, institutional organization, education,
practice, and research of Ayurveda from selected sources
mentioned in Further Readings at the end of this paper.)
CAM and Ayurveda Related Drug Research in Liver Diseases
including Hepatic Cirrhosis. Searching commonly accepted
sources, only a paucity of scientifically evaluated CAM-
options for the treatment of chronic liver diseases, especially
of cirrhotic liver conditions, is retrievable.
S-Adenosylmethionine,polyenylphosphatidylcholine, be-
taine, and antioxidants like vitamins A, C, E, B6, and B12
as well as branched chain amino acids are examples of
substances studied for their potential efficacy in cases of
hepatic cirrhosis. Trials showed clinical improvements, but
hardly any statistically significant improvements in liver
function test [19–29].
For herbal drugs used in different fields of CAM limited
data is available, which have shown beneficial effects on
liver diseases in clinical trials [30–33]. Worldwide, Silybum
marianum (L.) Gaertn. is currently the plant on which most
research has been performed in the treatment of liver diseases
[34–38]. From East Asia, the compound herbal drug TJ-9
is worth mentioning for chemoprevention in hepatocellular
carcinoma, commonly prescribed as Xiao-Chai-Hu-Tang in
China and as Sho-Saiko-To in Japan. It consists of an extract
from the roots of Scutellaria baicalensis Georgi, Glycyrrhiza
glabra L., Bupleurum falcatum L., and Panax ginseng C. A.
Mey [39].
CAM research on chronic liver diseases also incorporates
drugs commonly used in Ayurveda. Nobel laureate Baruch
Blumberg, awarded for his hepatitis B virus surface-antigen
discovery, had already in the 1980s initiated research on
Phyllanthus niruri Sensu Hook. F. non Linn. (P. niruri),
seeking measures to prevent and treat hepatitis B [40].
Reviews in recent years come to conclusions varying from
being positive to being indifferent regarding P. niruri’s effect
in this condition [41–43]. As an example among animal
studies, carbon tetrachloride- (CCl4-) induced increase of
serum glutamic-pyruvic transaminase (ALT) and elevation
of MDA in liver of mice are significantly lowered by P.
niruri in vivo and the coincubation of isolated rat hepatocytes
with P. niruri in vitro significantly inhibits CCl4-induced
decrease ofmobility ofmembrane of liver cells and increase of
intracellular free Ca∼(2+)([Ca∼(2+)] (i)) concentrations of
liver cells.These results suggest that the antilipid peroxidation
effect and protection of membranes through P. niruri may
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be related to its protective action against CCl4-induced liver
injuries [44].
The positive action in chronic liver diseases of Liv 52, an
Ayurvedic herbal compound preparation frequently used in
India for chronic liver diseases, is well documented [45].
Piper longum Linn. fruit (P. longum), a traditional medic-
inal plant in Ayurveda, was examined for its hepatoprotective
properties, concentrating on its main active ingredient piper-
ine, whichwas reported to exert significant protection against
acetaminophen-induced hepatotoxicity in mice [46].
Another medicinal plant in this context is Picrorhiza
kurroa Royle ex Benth (P. kurroa). Cucurbitacin glycosides,
isolated from the root of P. kurroa, exhibited liver protective
and anti-inflammatory activities. Kutkin, a glycosidal bitter
component of P. kurroa exhibited hepatoprotective activity in
alcohol-induced hepatotoxicity in rats [47–51].
Boerhavia diffusa L. (B. diffusa) exhibits anti-inflamma-
tory, hepatoprotective, and antioxidant effects and therefore
can be considered as an option in cases of HCcA [52–55].
Tephrosia purpurea Pers. (T. purpurea) is widely used in
the treatment of inflammation of the spleen and liver in
the Ayurvedic tradition. Its powdered aerial parts prevent
an elevation of GOT, GPT, and bilirubin levels [56, 57].
The cirrhotic and nodular changes induced by CCl4 were
effectively prevented by T. purpurea showing that it might
be acting by stabilizing cell membranes. These findings relate
to an earlier study which reported that pretreatment of rats
with Tefroli, a herbal product containing T. purpurea as one
of the main ingredients, protected the rats against progress of
hepatic fibrosis after chronic CCl4 intoxication [58].
Finally, Eclipta alba (L.) Hassk. (E. alba) holds a promi-
nent position in the traditional use for hepatitis and spleen
enlargements inAyurveda and is considered to be a liver tonic
[59]. The protective effect of E. alba on carbon tetrachloride-
induced acute liver damage was also studied in 54 female
guinea pigs in an experimental trial [60].
Hence, over the last years and decades, several research
projects were dedicated to examining the effects of herbal
drugs traditionally used in Ayurveda to support liver func-
tions and treat common liver diseases. However, the effects
of CAM herbal therapies on life-threatening chronic liver
diseases have for the most part been evaluated on animal
studies. Among the limited number of CAM clinical trials
only a few deal with hepatic cirrhosis and so far no clinical
study is known to the authors, which has directly evaluated
Ayurvedic therapies in patients with HCcA.
Rationale for the Ayurvedic Treatment Protocol of the Present
Study. On the basis of this preliminary evidence and as com-
monly practiced in the field of reverse pharmacology, treat-
ment protocols incorporating empirical data from traditional
treatment patterns of WMS Ayurveda can be considered as
promising and ethically sound. In this sense, a standardized
treatment protocolwas developed from traditional Ayurvedic
sources, supplemented by current research findings. It was
implemented for several years at the P. D. Patel Ayurveda
Hospital in Nadiad, India, before this observational study
was conducted. Special attentionwas given to the proposition
that medicinal plants exert more intense action, if embedded
in complex treatment schemes. In Ayurveda, certain prepara-
tory measures such as purificatory procedures (e.g., purga-
tion) are considered to enhance the action of drugs. Also diet
and lifestyle corrections are held to optimize the effect of any
given treatment [61].
In current Ayurveda, HCcA is commonly related to
the superordinate disease group of the so-called abdominal
diseases (udara roga). Among eight types of “abdominal
diseases” the most serious conditions are considered to be
jalodara or yakriddaludara, which can be interpreted as
different varieties of HCcA [62]. These nosological entities
are described as having similar symptoms to another form of
“abdominal disease” (plihodara) characterized by abdominal
distention (due to splenomegaly), accompanied by weakness,
anorexia, indigestion, constipation, excessive thirst, breath-
lessness, coughing, vomiting, cachexia, syncope or coma, and
visible yellowish or indigo colored veins in the abdominal
area [63].
The treatment protocol for the study was predominantly
inspired by one of the most authoritative texts of Ayurveda
(the Caraka Samhita). Initially, a procedure, which consists
of a specific administration pattern of P. longum in increasing
and tapering doses (vardhamana-pippali-rasayana, Table 2)
[64], was performed on all patients.Themicrofine powder of
dried P. longum fruit (family Piperaceae) was manufactured
with the help of pulverizing machines by Sundar Ayurveda
Pharmacy, that is, the pharmacy of the Pharmaceutical
Department of J. S. Ayurved College, Nadiad, India, as all
the following powders of dried plants. A large number of
alkaloids and related compounds, the most abundant of
which is piperine, together withmethyl piperine, iperonaline,
piperettine, asarinin, pellitorine, piperundecalidine, piper-
longumine, and piperlonguminine are found in the fruit.
According to classical Ayurveda, this procedure exerts a
tissue-regenerating effect (rasayana), which can be inter-
preted as being hepatoprotective. The classical dosage pat-
terns were found to be intolerable for patients of our hospital
before the commencement of the study. Consequently, the
study intervention was standardized to a lower dosage pat-
tern.
Themultidimensional approach of Ayurveda calls for cer-
tain “purificationmeasures” inmost diseases.Here, purgation
induced by rhizomes and roots of P. kurroa was chosen in a
dosage matched with the individual condition of each patient
[65]. The powder of dried roots and rhizomes of P. kurroa
(family Scrophulariaceae)mainly contains iridoid glycosides,
cucurbitacins, unsaturated sterols/triterpenes, and polyphe-
nols, especially kutkin, a bitter glycoside.
These “preparatory” treatments were embedded in a set
of strict food and behavioral restrictions, based on classical
Ayurvedic rationales [66]. Namely, a diet consisting only
of boiled milk and maximum rest in an OPD setting were
implemented.
Classically indicated drugs, like the powder of dried
whole plants of B. diffusa, T. purpurea, and E. alba, were ad-
ministered since the experimental studies cited above suggest
a hepatoprotective action of these drugs and because (empir-
ically) the combination of these drugs has been used for
the treatment of HCcA over centuries in routine Ayurvedic
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therapy. B. diffusa (family Nyctaginaceae) contains mainly
alanine, arachidic acid, aspartic acid, behenic acid, boeravi-
nones A through F, boerhaavic acid, and borhavine. In T. pur-
purea (family Fabaceae) the presence of flavones, flavanones
(e.g., purpurin) and prenylated flavonoids, chalcones, and
rotenoids was found. From E. alba, Ecliptasaponin C, a new
triterpenoid glucoside, was isolated togetherwith daucosterol
and stigmasterol-3-O-glucoside.
To promote diuresis, the herbal compound formulation
Punarnavadi-kvatha [67] based on the whole plant of B.
diffusa and the herbomineral combination Shveta-Parpati
[68] were chosen. The ingredients of Punarnavadi-kvatha
are listed in Table 3. The method of preparation follows
the description of ancient Ayurvedic texts for decoction
(kvatha). 10 g of the course powder of mentioned dried
plants are boiled in 160mL water in an open vessel on mild
heat until it is reduced to one-fourth of the original water
quantity (40mL). This preparation is boiled fresh twice daily
and administered orally after cooling down. Shveta-Parpati
contains ashes of 1 g ammonium chloride [NH
4







O], and 16 g potassium nitrate which
are purified according to the classical method. All ingredients
were triturated and afterwards deposited in a sealed earthen
pot, which was kept in a furnace with fire for 8 hours. Then
they were allowed to cool and powdered.
To this effect, the present nonrandomized, uncontrolled,
single group, open-label observational clinical study scientif-
ically explores effectiveness and safety of a treatment scheme,
which generated clinically promising results in single cases
of hepatic cirrhosis complicated by ascites in an Ayurvedic
hospital.
2. Materials and Methods
2.1. Research Center. The P. D. Patel Ayurveda Hospital is
a university teaching hospital of the J. S. Ayurved College,
accredited by the Indian Government for under- and post-
graduate Ayurveda education and run by a private charitable
trust, the Mahagujarat Medical Society in Nadiad, India. All
participants were screened and treated in both the in-patient
department (IPD) and out-patient department (OPD) of the
clinic.
The Institutional Ethics Committee of J. S. Ayurveda
Mahavidyalaya, Nadiad, India, has given its permission to
publish the data under the approval number 18/02-2014
(reference letter JSAM/14-15/26).
The laboratory consulted for all mentioned investigations
is a part of the research center.
Adhering to standard operating procedures (SOP) and to
classical descriptions all medicaments were purchased from
Sundar Ayurveda Pharmacy, which is preparing all main
Ayurvedic pharmaceuticals for the campus hospital. Collec-
tion of the used plant material complied with institutional,
national, or international guidelines.
2.2. Patient Selection. The involved human subjects were all
above 18 years of age. They were informed about the study
details and gave consent to record and publish their data.
Datasets were handled and displayed in a way which does
not compromise anonymity or confidentiality or breach local
data protection laws. Being an observational study, patients
were chosen according to the inclusion and exclusion criteria.
Inclusion criteria were as follows: positive patient history
and established diagnosis ofHCcA according to international
standards [15]; manifest clinical features, especially oedema,
loss of appetite, general weakness, nausea and vomiting,
increased measurement of abdominal girth (sign of ascites),
and decreased urine output; manifest laboratory findings,
especially hyperbilirubinemia, decreased serum albumin
level, decreased albumin/globulin (A/G) ratio, raised serum
alkaline phosphatase, raised liver transaminase enzymes, and
confirmed abdominal ultrasound diagnosis of HCcA.
Exclusion criteria were as follows: hepatic cirrhosis due to
cardiac causes, inherited metabolic causes, haemochromato-
sis and Wilson’s disease; recent (≤3 month) life-threatening
complications (like encephalopathy and excessive gastroin-
testinal bleeding), and other major comorbidities (like
insulin-dependent diabetes mellitus, bleeding piles, manifest
heart diseases, and renal failure). Female patients having
pregnancy, postdelivery period, or lactation period and
patients who were taking any psychiatric or other liver
damaging medicines were also excluded.
Screening was performed between January 2007 and
December 2010.
2.3. Study Protocol and Timeline. The study was planned to
generate first exploratory data on the potential of Ayurvedic
medicine for advanced liver diseases.
After screening, the main IPD observation period lasted
for 6 weeks followed by an OPD follow-up of 18 weeks
resulting in an overall 6-month observation period. During
follow-up, patients were investigated for signs, symptoms,
and laboratory findings (Table 1).
2.4. Therapy. The treatment conducted is standard care and
best practice for the given disease at our hospital. All patients
were treated according to the following treatment protocol
standardized on the basis of classical Ayurvedic literature and
traditional treatment patterns.
2.4.1. Phase 1. At the beginning of the IPD period, finely
powdered dried fruit of P. longum was administered orally in
an increasing and tapering dose pattern twice daily with milk
before meals. This classical procedure was performed for a
period of 13 days (Table 2).
2.4.2. Phase 2. On the morning of the 14th day, mild
purgation was performed once, orally administering finely
powdered dried rhizomes and roots of P. kurroa with warm
water on an empty stomach in varying doses from 3 to 6 g
according to the patients’ individual sensitivity to purgatives
(koshtha).
2.4.3. Phase 3. For the next 4 weeks a number of Ayurvedic
drugs were given orally twice daily after meals (Table 3).
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Table 1: Timeline of the study.
Phase Event Measure Week
Prephase Screening (i) Inclusion and exclusion criteria Week 0
Main observation
period (IPD) Baseline visit (V0)
(i) Clinical and laboratory investigations




(i) Piper longum Linn. administration (specific dose
pattern)
(ii) Strict diet and lifestyle measures
Weeks 1 & 2
(days 1–13)
Phase 2 (i) Purgation(ii) Strict diet and lifestyle measures
Week 2
(day 14)
Phase 3 (i) Drug administration(ii) Strict diet and lifestyle measures Weeks 3–6
First visit (V1) (i) Clinical and laboratory investigations(ii) Discharge from IPD Week 7
Follow-up (OPD)
Phase 4
(i) Continued drug administration
(ii) Diet and lifestyle measures Weeks 7–24
Second visit (V2) (i) Clinical and laboratory investigations Week 24
Table 2: Dose pattern of Piper longum Linn.
Day 1 2 3 4 5 6 7 8 9 10 11 12 13
Dose [g]
twice daily





2.4.4. Diet and Lifestyle. In the IPD phase, a set of rigorous
food (boiled pasteurized fat-free cow’s milk) and behavioral
restrictions (maximum rest in an IPD setting) was carried
out. The participants were allowed to consume milk accord-
ing to their digestive capacity varying from 2 to 3.5 litres per
day. All other liquids and foods were prohibited.
2.4.5. Conventional Medication. Patients on conventional
diuretics (e.g., furosemide and spironolactone) were advised
to continue their medication initially. Their dosage was
gradually reduced according to decreasing oedema as well as
abdominal girth and increase in urine output and eventually
stopped as soon as the patient responded to the Ayurvedic
treatment satisfactorily.
2.4.6. Phase 4. During follow-up, patients were advised
to continue all Ayurvedic medicaments at home except P.
longum. In diet, they were instructed to take a special type
of boiled beans (Vigna radiata (L.) Wilczek), rice, and boiled
vegetables being easily digestible and nonslimy in consis-
tency. Also nonsour fruits, like papaya, mango, sweet apple,
and so forth, were permitted. All participants were strictly
told to permanently abstain from all alcoholic beverages.
2.5. Assessment of Results. Treatment effects were measured
by a predefined set of typical clinical features and laboratory
parameters of HCcA. Additionally, the assessed outcomes
included prognostic markers according to the Child-Pugh
grade score.
2.5.1. Clinical Features (Scores). Following clinical features
were selected as representative markers for the assessment of
HCcA treatment during study visits (V0–V2): oedema, loss of
appetite, general weakness, nausea and vomiting, abdominal
girth, and daily urine output.
They were graded according to the score presented in
Table 4. Changes in ascites were assessed by themeasurement
of abdominal girth and urine output in liters per day. All other
investigations were also recorded before (V0) and after (V1)
treatment and also during follow-up (V2).
Statistically, all outcomes were analyzed using a paired
Student’s test (“t” test). Explorative tests were not adjusted
for multiple testing. A value of 𝑝 < 0.05 was considered as
statistically significant and 𝑝 < 0.001 as statistically highly
significant.
3. Results
3.1. Baseline (V0). 68 patients (48males and 20 females) with
HCcA were screened. Mean age was 46.45 years (<20 years
of age: 𝑛 = 2; 20–40 years of age: 𝑛 = 25; >40 years of age:
𝑛 = 41).
12 drop-outs happened due to personal reasons not
related to the therapy, like social or family affairs (e.g.,
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Table 3: Treatment protocol for Ayurvedic drugs.
Number Botanical name Ayurvedic name Content ratio Part used Form Dose
(1) Compound decoction Punarnavadi-kvatha Various Coarsepowder/decoction 10 g/40mL
(a) Boerhavia diffusa L. L.Linn. Punarnava 1 part Whole plant Coarse powder
(b) Berberis aristata DC. Daruharidra 1 part Whole plant Coarse powder
(c) Cyperus rotundus L. Musta 1 part Root Coarse powder
(d) Curcuma longa L. Haridra 1 part Rhizome Coarse powder
(e) Azadirachta indica A.Juss. Nimba 1 part Bark Coarse powder
(f)
Tinospora cordifolia
(Willd.) Hook. F. &
Thoms.
Guduci 1 part Stem Coarse powder
(g) Zingiber officinale Rosc. Shunthi 1 part Rhizome Coarse powder
(h) Picrorhiza kurroa Royleex Benth. Katuki 1 part Root Coarse powder
(2) Compound powder Fine powder 5.5 g
(a) Tephrosia purpurea Pers.Linn. Pers. Sharapunkha Root Fine powder 2 g





Navasara 1 part Ultrafine powder(ash)
(II) Potassium nitrate[KNO3]
Suryakshara 16 parts Ultrafine powder(ash)
(III) Potash alum[KAl(SO4)212H2O]
Sphatika 2 parts Ultrafine powder(ash)
(3) Eclipta alba (L.) Hassk. Bhrngaraja Whole plant Fine powder 3 g
Table 4: Assessed clinical features’ score (Grade 0–3).
Number Symptom Grade 0 Grade 1 Grade 2 Grade 3













(3) General weakness No weakness Mild weakness Moderateweakness Severe weakness
(4) Nausea andvomiting Absent Occasional
Once or twice a
week Daily
(5) Abdominal girth[cm] Grading per [cm]-scale
(6) Urine output[L/day] Grading per [L]-scale
marriages or death of close family members, which are of
major social relevance in South Asia). Overall, 56 patients’
datasets were completely recorded.
Prolonged alcohol consumption and cryptogenic cirrho-
sis of liver were found asmain causative factors in 26 patients.
A positive patient history for different forms of hepatitis
was present in 16 cases (Table 5). At the time of study entry
(V0), all patients were treated with standard conventional
medicine.
3.2. Treatment Effects
3.2.1. Clinical Features. Oedema was reduced by 83.9%.
Appetite increased by 64.7%. General weakness declined
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Figure 1: Effect on prognosis according to Child-Pugh grade score: overall change (𝑛 = 56).
Table 5: Baseline (V0) characteristics: underlying causes of HCcA
(𝑛 = 68).





Alcohol and Hepatitis B 6 9
Hepatitis B 8 12
Hepatitis C 2 3
Cryptogenic cirrhosis 26 38
by 54.7%. Nausea and vomiting were relieved by 90.9%.
Abdominal girth decreased by 19.7%. Urine output increased
by 266.3%. All these clinical features were found to be
statistically highly significant (𝑝 < 0.001) (Table 6).
3.2.2. Laboratory. Accordingly, all relevant laboratory val-
ues improved in a statistically significant fashion; albumin
(40.7%) and bilirubin (66.5%) (Table 7) were mostly pro-
nounced.
3.2.3. Child-Pugh Grade Score. At baseline (V0) 19 patients
were graded in Group C (worst prognosis), 36 patients were
graded in Group B (medium prognosis), and 1 was graded
patient in Group A (best prognosis). After treatment (V1) 50
patients were found in Group A, 6 patients were found in
Group B, and no patient was found in Group C (Figure 1).
56 patients completed the full 6-months treatment proto-
col. They adhered to the dietary and lifestyle advice and took
their medicines regularly. During follow-up (V2) patients’
general condition further improved and no setback of clinical
features was observed. Liver function tests also further
improved (see Table 7). With regard to the Child-Pugh grade
score, 6 patients of Group B returned to Group A after
completing the follow-up period; that is, all patients came to
group A.
4. Discussion
In this study improvements in all clinical features and
laboratory parameters were observed. The results were clin-
ically relevant and statistically significant. Notably, albumin
synthesis was initially impaired in all cases, but under this
Ayurvedic treatment protocol albumin levels increased in all
patients. Ascites could be reversed and controlled. None of
the patients developed severe adverse effects or new compli-
cations and hence the treatment was found to be safe under
the given conditions. Notably, in all participants conventional
medication could be reduced or even withdrawn. Initially
indicated invasivemeasures (e.g., liver transplantation) could
be omitted, particularly through improvements of the Child-
Pugh grade score in several patient cases. Patients were able to
manage their routine everyday life affairs without becoming
dependent on cost intensive conventional health care and
maintenance measures within the observation period.
Hence, the treatment protocol can be considered as
applicable and cost-effective and, probably, as a template for
subsequent trials in this field. These results are promising
and may be regarded as a novelty in clinical research
on hepatic cirrhosis complicated by ascites, looking at an
overall paucity of peer-reviewed publications on Ayurvedic
treatment options in this field [61–66], and an absence of
respective clinical study data available in internationally
accessible medical databases.
From a conventional biomedical perspective, the proba-
ble mode of action of the study drugs may stem from their
effects on specific metabolic liver functions and functions
of associated organs, the details of which have still to be
subject to future studies [40–60]. Taking the traditional
Ayurvedic paradigms into account and Ayurveda’s unique
understanding of pathogenesis and treatment, more general
terms should be used to explain their modes of action. Along
the way, the challenges and problems arising in translational
processes between systems’ terminology remain an open
field of study, in particular for qualitative research on WMS
[67]. In summary, the study drugs’ antioedemic, diuretic,
immunomodulatory, rejuvenative, hepatosplenoprotective,
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Table 6: Changes in clinical symptoms from baseline (V0) to week 7 (V1).
Number Symptom score Mean score Improvement [%] 𝑝 value
Baseline (V0) Week 7 (V1)
(1) Oedema score 2.01 ± 0.68 0.33 ± 0.57 83.87 ± 0.62 <0.001
(2) Loss of appetite score 2.62 ± 0.53 0.92 ± 0.52 64.70 ± 0.51 <0.001
(3) General weakness score 2.67 ± 0.47 1.21 ± 0.5 54.67 ± 0.58 <0.001
(4) Nausea and vomiting score 1.29 ± 0.59 0.12 ± 0.33 90.90 ± 0.4 <0.001
(5) Abdominal girth [cm] 89.9 ± 10.6 72.1 ± 9.76 19.7 ± 7.17 <0.001
(6) Urine output [liter/per day] 0.45 ± 0.29 1.63 ± 0.58 266.32 ± 0.5 <0.001
Table 7: Changes in clinical laboratory: baseline (V0), week 7 (V1), and follow-up (V2).
Investigation Mean score Improvement in percent [%] 𝑝 value
Baseline (V0) Week 7 (V1) After 6 months (V2) After Week 7 (V1) Between V1 and V2
Serum bilirubin [mg/dL] 3.74 ± 4.59 1.25 ± 1.31 0.94 ± 0.63 66.5 ± 4.04 25.63 ± 0.70 <0.001
Serum albumin [g/dL] 2.71 ± 0.67 3.32 ± 0.45 3.43 ± 0.28 22.43 ± 0.54 3.27 ± 0.29 <0.001
Serum albumin/serum
globulin [A/G] 0.73 ± 0.20 1.03 ± 0.20 1.17 ± 0.17 40.65 ± 0.19 13.33 ± 0.17 <0.001
Serum alkaline
phosphatase [IU/L] 318.3 ± 102.2 210.8 ± 53.05 192.15 ± 29.42 33.8 ± 76.37 8.37 ± 30.60 <0.001
Serum globulin [g/dL] 3.77 ± 0.62 3.27 ± 0.43 2.96 ± 0.32 13.3 ± 0.51 9.33 ± 0.37 <0.001
Hemoglobin [g/dL] 8.78 ± 1.90 10.36 ± 1.52 11.33 ± 1.47 17.98 ± 0.93 9.36 ± 1.06 <0.001
Serum GPT [IU/L] 58.41 ± 44.38 40.62 ± 27.6 30.62 ± 9.07 30.5 ± 27.39 24.60 ± 21.62 <0.001
Serum GOT [IU/L] 84.52 ± 50.52 52.6 ± 31.21 44.27 ± 21.81 37.8 ± 34.92 14.67 ± 14.63 <0.001
and metabolism-promoting actions may be considered as
being mainly responsible for the observed effects [68–75].
4.1. Limitations and Future Directions. The study is a non-
randomized, uncontrolled, single group, open-label obser-
vational clinical study. This design therefore bears major
limitations. Various nonspecific effects, the setting, and the
time course may have contributed to the beneficial course
of the disease. Thus they may have influenced the results.
Furthermore, changes in diet and the restricted alcohol
consumption may have influenced the results. If the study
therapies would have been studied with more patients and
under controlled, randomized conditions, the effectiveness of
the therapy could have been presented with more power, cer-
tainty, and accuracy. Another limitation is that patients with
serious complications like severe gastrointestinal bleeding
and hepatic encephalopathy were not included in this study.
Though important for the Child-Pugh Score, patients with
hepatic encephalopathy were a priori excluded during the
screening process. Moreover, the inclusion of further assess-
ment criteria like lipid profile data, PBMC transcripts profiles
or miRNA evaluations, pre- and posttreatment USG, and
liver biopsies would be helpful to give clues on histological
changes in future studies. From awhole systems perspective it
might also be considered a limitation that mind-body aspects
of Ayurvedic medicine were not included in the treatment
protocol [76].
Notably, the transferability of these results to Western
clinical contexts, particularly looking at Ayurvedic treatment
availability, economic aspects, and safety issues, remains
another important field of discussion [77, 78]. For example,
many of the therapies and drugs used in this study are
not commonly available in Western countries, especially not
in standardized and rigorously tested dosage forms, and,
moreover, are usually much more expensive than in their
countries of origin.Thus, the conclusions of this study remain
to some extent regional to South Asia where Ayurveda is a
recognized as a full-fledged and widely practiced system of
medicine [79].
5. Conclusions
On the basis of these findings, the Ayurvedic treatment
protocol could be a potentially safe and effective complement
in the case of HCcA therapy. If replicated in larger trials,
Ayurvedic medicine could represent a promising tool to
postpone the need of liver transplantations, increase the
QoL of patients with HCcA, and reduce overall treatment
costs. However, randomized and controlled studies with
larger numbers of patients are indicated to further evaluate
the results of this Ayurvedic treatment protocol. Cross-
cultural and interdisciplinary aspects should also be taken
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B. diffusa: Boerhavia diffusa L.
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